For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Buprenorphine - Pain (non-malignant)
PAD Profile : Buprenorphine - Pain (non-malignant)
Traffic Light Status
Status 1 of 2.
- Buccal/sublingual
Status 2 of 2.
- Patches
Guidelines
No guidelines returned.
Other Drugs
- Tapentadol hydrochloride
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Tramadol hydrochloride
- Codeine phosphate
- Morphine sulfate
- Pregabalin
- Gabapentin
- Meptazinol hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
It is recommended that buprenorphine patches are prescribed by BRAND - see UKMI Branded Prescribing Recommendations document. The locally preferred brand for buprenorphine 7-day patches is Butec® Butec® is available across all of the dose ranges, already represents the most commonly prescribed brand nationally (>50%), and is considerably less costly than the originator brand BuTrans. Patients currently receiving generically written prescriptions should be reviewed with a view to change the prescribing to a cost-effective brand.
A stepped approach to pain management is recommended. Paracetamol is considered a 1st line option for the treatment of pain.
Sub-lingual / buccal - consider for use patients who are unable to tolerate standard codeine/ dihydrocodeine tablets or capsules or if morphine is contra-indicated.
Patches - (low dose) for use in the limited number of patients who are unable to tolerate oral medications or if morphine is contra-indicated. Higher dose buprenorphine patches are not included in the pathway within this guideline and have a limited place in therapy for persistent non-malignant pain.
Please refer to the guidelines.
Consider a patient agreement is completed by the patient (see below) prior to a trial of Buprenorphine.